Consequently, allele‐specific silencing is clearly identified as a promising therapeutic strategy for AD‐CNM, allowing envisions of a treatment for this neuromuscular disorder and in extension to other DNM2‐linked inherited diseases. Here, DNM2 is linked to hereditary disease.